The Oncology Institute, Inc. TOI Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Other Operating Income by Business | ||||||
| Clinical trials & other | $3.28M-51.0% | $4.24M-39.5% | $5.46M-18.1% | $6.54M-1.4% | $6.69M-0.3% | |
| Patient services | $17.43M+16.7% | $17.7M+45.8% | $14.28M-12.6% | $13.47M-33.2% | $14.94M-34.7% | |
| Total segment amortization by Business | ||||||
| Clinical trials & other | $55K-80.0% | $110K-60.0% | $220K+1.4% | $275K+27.9% | $275K+29.1% | |
| Patient services | $2.87M-20.1% | $2.87M-20.1% | $3.59M+25.0% | $3.59M+24.5% | $3.59M+26.4% | |
| Total Assets by Business | ||||||
| Clinical trials & other | $20.27M-41.1% | $22.24M-38.7% | $24.78M-33.4% | $29.16M-20.7% | $34.4M-4.2% | |
| Patient services | $301.89M+8.8% | $284.53M-1.8% | $278.32M-5.6% | $276.8M-8.4% | $277.49M-10.5% | |
| Depreciation expense by Business | ||||||
| Clinical trials & other | $8K-76.5% | $10K-68.8% | $4K-86.7% | $4K-87.1% | $34K+3,300% | |
| Patient services | $2.9M+15.7% | $2.92M+28.8% | $2.95M+38.7% | $2.77M+19.6% | $2.51M+10.7% | |
| Total operating revenue by Product | ||||||
| Capitated revenue | $89.92M+31.2% | $80.48M+17.2% | $74.42M+6.1% | $68.66M-6.4% | $68.51M-4.1% | |
| Clinical trials & other | $3.33M-59.0% | $4.56M-47.0% | $6.32M-22.5% | $7.79M-0.6% | $8.12M+4.8% | |
| FFS revenue | $145.09M+5.9% | $148.51M+9.0% | $144.96M+3.0% | $140.27M-0.8% | $136.98M-5.0% | |
| Patient services | $235.01M+14.4% | $228.99M+11.8% | $219.37M+4.0% | $208.93M-2.7% | $205.5M-4.7% | |
| Total Assets by Product | ||||||
| Capitated accounts receivable | $9.95M— | $12.26M— | $12.75M— | —— | —— | |
| FFS accounts receivable | $136.25M— | $131.2M— | $122.36M— | —— | —— | |
| IV drug inventory | $36.52M— | $29.5M— | $27.97M— | —— | —— | |
| Oral drug accounts receivable | $37.56M— | $35.18M— | $34.1M— | —— | —— | |
| Oral drug inventory | $39.31M— | $34.36M— | $29.04M— | —— | —— | |
| Other assets | $140.28M— | $127.6M— | $135.43M— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does The Oncology Institute, Inc. break its business down?
- The Oncology Institute, Inc. (TOI) reports other operating income by business across 3 parts — Clinical trials & other, Patient services and Specialty pharmacy. Each is extracted from the segment footnotes and tracked over time.
- Where does The Oncology Institute, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in The Oncology Institute, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
